Durham-based biotechnology startup Tavros Therapeutics has announced its second collaboration in six months to find new targets and therapies for cancer. Here’s the latest in our Startup Spotlight.
Read More
Durham-based biotechnology startup Tavros Therapeutics will partner with Bayer AG subsidiary Vividion Therapeutics to find new targets and treatments for cancer. Here’s a detailed look at the deal.
Read More
RTP oncology firm Tavros Therapeutics has entered into a collaboration with a wholly-owned subsidiary of Bayer AG.
Read More
The Durham-based oncology startup Tavros Therapeutics has closed a second seed round of $7.5 million, following a $3 million initial raise in 2020.
Read More
Under the arrangement, the Durham-based emerging biotech company — founded by Duke grad Eoin McDonnell — will apply its genomic discovery platform to develop next generation target small molecule drug candidates, initially to expand Zentalis’ oncology pipeline.
Read More
Eoin McDonnell founded Tavros in October 2019. He is a former senior scientist with Element Genomics, a Duke-spinout company focused on using CRISPR/Cas9-based tools to discover novel regulatory elements in the genome. It was acquired by UCB Pharma in 2018.
Read More
